What happens during the study?
The study has a 28-day Screening Period, a Study Treatment Period, a Short-Term Follow-up Period, and a Long-Term Follow-up Period.
You will be in the study for about 5 years. How long you take the study treatment depends on how your cancer responds to it and how your body handles any possible side effects.
Screening Period
If you decide to take part in the study, some tests will be done to see if you are eligible to join.
Study Treatment Period
You have a 2 in 3 chance of being assigned to the group that gets the study drug Xaluritamig. You have a 1 in 3 chance of being assigned to the group that gets an existing treatment option. You or your study doctor cannot choose which group you are placed in. There is no placebo in this study.
Short-Term Follow-up Period
After you stop taking your assigned study treatment, the study doctor will give you a final checkup.
Long-Term Follow-up Period
A member of the study staff will continue to check in on you. You may be contacted by phone or asked to come in for checkups or imaging scans.
